Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Decoding tumor immune microenvironment heterogeneity by single-cell and spatial multi-omics: From immunotherapy resistance to translational biomarkers. Local targets link to admitted publications; unresolved targets remain external evidence.
The tumor microenvironment's role in the response to immune checkpoint blockade
10.1038/s43018-025-00986-3 · 2025 · External reference
Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy
10.3389/fimmu.2021.754196 · 2021 · External reference
Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
10.1172/jci184043 · 2025 · External reference
Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
10.1016/j.ccell.2023.07.011 · 2023 · External reference
Regulatory T cells in immune checkpoint blockade antitumor therapy
10.1186/s12943-024-02156-y · 2024 · External reference
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
10.1136/jitc-2024-011377 · 2025 · External reference
The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
10.1016/j.cell.2022.09.020 · 2022 · External reference
Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma
10.1038/s41588-025-02077-6 · 2025 · External reference
Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer
10.1158/0008-5472.can-20-1674 · 2021 · External reference
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
10.1016/j.ccell.2024.11.008 · 2025 · External reference
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care
10.1080/17474124.2021.1864325 · 2021 · External reference
Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS® and neoadjuvant treatment
10.1016/j.ejso.2022.12.006 · 2023 · External reference
Hacking pancreatic cancer: present and future of personalized medicine
10.3390/ph14070677 · 2021 · External reference
Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group?
10.1016/j.euo.2023.07.003 · 2024 · External reference
DNA damage response alterations in gastric cancer: knocking down a new wall
10.2217/fon-2020-0989 · 2021 · External reference
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis
10.1038/s41598-024-71746-z · 2024 · External reference
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
10.1136/jitc-2024-010311 · 2025 · External reference
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
10.1038/s41568-024-00705-7 · 2024 · External reference
The challenges of tumor mutational burden as an immunotherapy biomarker
10.1016/j.ccell.2020.10.001 · 2021 · External reference
Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
10.1158/1078-0432.ccr-23-3403 · 2024 · External reference
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives
10.1186/s13045-025-01732-z · 2025 · External reference
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
10.1038/s43856-024-00687-5 · 2024 · External reference
Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies
2024 · External reference
Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability
10.1016/j.annonc.2023.05.010 · 2023 · External reference
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
10.1016/s1470-2045(22)00783-5 · 2023 · External reference
SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
10.1186/s12885-023-10920-4 · 2023 · External reference
Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance
10.1080/08923973.2025.2504906 · 2025 · External reference
Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer
10.1126/scitranslmed.adh8005 · 2023 · External reference
Molecular patterns of resistance to immune checkpoint blockade in melanoma
10.1038/s41467-024-47425-y · 2024 · External reference
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
10.1016/j.imlet.2019.03.006 · 2020 · External reference
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
10.1038/s41588-024-01998-y · 2025 · External reference
CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review
10.1002/jcp.27782 · 2019 · External reference
Innate and adaptive immune cells in the tumor microenvironment
10.1038/ni.2703 · 2013 · External reference
IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma
10.1093/neuonc/noae126 · 2024 · External reference
Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8(+) T and CAR-T cells
10.1016/j.ymthe.2024.08.019 · 2024 · External reference
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
10.1038/s41587-023-02060-8 · 2024 · External reference
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
10.1016/j.jhep.2024.12.016 · 2025 · External reference
Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options
10.1016/j.pharmthera.2022.108253 · 2022 · External reference
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
10.1126/science.aad0501 · 2016 · External reference
Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
10.1186/s12916-023-02866-y · 2023 · External reference
Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
10.1038/s41467-024-52977-0 · 2024 · External reference
Pan-cancer single-cell landscape of tumor-infiltrating T cells
10.1126/science.abe6474 · 2021 · External reference
A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
10.1016/j.cell.2021.01.010 · 2021 · External reference
Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer
10.1016/j.ccell.2022.04.011 · 2022 · External reference
Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells
10.1158/0008-5472.can-23-1448 · 2024 · External reference
Single-cell spatial landscapes of the lung tumour immune microenvironment
10.1038/s41586-022-05672-3 · 2023 · External reference
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
10.1038/s41588-025-02351-7 · 2025 · External reference
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer
10.1038/s41598-022-13855-1 · 2022 · External reference
Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer
10.1007/s00262-025-04189-8 · 2025 · External reference
SPP1(high) macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1/CD44/PI3K/AKT signaling
10.1136/jitc-2025-012330 · 2025 · External reference
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
10.1038/s41467-021-25962-0 · 2021 · External reference
Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy
10.1016/j.canlet.2019.11.009 · 2020 · External reference
Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity
10.1016/j.immuni.2022.12.008 · 2023 · External reference
Cancer immunotherapies: advances and bottlenecks
10.3389/fimmu.2023.1212476 · 2023 · External reference
Chemoradiotherapy-induced ACKR2(+) tumor cells drive CD8(+) T cell senescence and cervical cancer recurrence
2024 · External reference
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer
10.1016/j.compbiomed.2023.107066 · 2023 · External reference
Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing
10.1016/j.redox.2022.102463 · 2022 · External reference
Unlocking the potential of extracellular vesicle circRNAs in breast cancer: from molecular mechanisms to therapeutic horizons
10.1016/j.biopha.2024.117480 · 2024 · External reference
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer
10.1038/s41586-023-06733-x · 2023 · External reference
Human single cell RNA-sequencing reveals a targetable CD8(+) exhausted T cell population that maintains mouse low-grade glioma growth
10.1038/s41467-024-54569-4 · 2024 · External reference
Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer
10.1002/ctm2.1453 · 2023 · External reference
Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient
10.3389/fimmu.2022.985187 · 2022 · External reference
Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis
10.1053/j.gastro.2021.06.025 · 2021 · External reference
Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface
10.1038/s41467-021-26614-z · 2021 · External reference
Single-cell spatial immune landscapes of primary and metastatic brain tumours
10.1038/s41586-022-05680-3 · 2023 · External reference
Neoantigens combined with in situ cancer vaccination induce personalized immunity and reshape the tumor microenvironment
10.1038/s41467-025-60448-3 · 2025 · External reference
Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment
10.1016/j.cell.2022.10.006 · 2022 · External reference
Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma
10.1158/0008-5472.can-22-3034 · 2023 · External reference
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition
10.1136/jitc-2023-007230 · 2023 · External reference
Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy
10.1126/sciadv.adg0654 · 2023 · External reference
Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer
10.1053/j.gastro.2022.07.076 · 2022 · External reference
Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction
10.1186/s10020-022-00475-8 · 2022 · External reference
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics
10.1038/s41467-021-26951-z · 2021 · External reference
Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts
10.1158/2159-8290.cd-19-0094 · 2019 · External reference
Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer
10.1158/2159-8290.cd-20-1484 · 2022 · External reference
Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing
10.1096/fj.202200898r · 2022 · External reference
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity
10.1016/j.canlet.2025.217475 · 2025 · External reference
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts
10.7150/thno.68972 · 2022 · External reference
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML
2024 · External reference
Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47
10.1038/s43018-023-00691-z · 2024 · External reference
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma
10.1093/neuonc/noad257 · 2024 · External reference
CSF1R(+) myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
10.1016/j.ccell.2025.05.013 · 2025 · External reference
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
10.1038/s41467-022-31764-9 · 2022 · External reference
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
10.1084/jem.20231106 · 2025 · External reference
FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions
10.1016/j.jare.2024.12.026 · 2025 · External reference
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
10.1016/j.ebiom.2024.105003 · 2024 · External reference
Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma
10.1097/js9.0000000000002568 · 2025 · External reference
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures
2025 · External reference
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy
10.1016/j.ejca.2025.115572 · 2025 · External reference
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
10.1016/j.celrep.2024.114392 · 2024 · External reference
Insights gained from single-cell analysis of immune cells in the tumor microenvironment
10.1146/annurev-immunol-110519-071134 · 2021 · External reference
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
10.1038/s41467-020-16164-1 · 2020 · External reference
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity
10.1016/j.ccell.2021.06.017 · 2021 · External reference
Tumor-associated macrophages produce PGE2 to promote CD8+ T-cell exhaustion and drive resistance to PD-L1 blockade in microsatellite-stable colorectal cancer
10.1158/0008-5472.can-25-0079 · 2026 · External reference
Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy
10.1038/s41416-025-03088-0 · 2025 · External reference
Spatial and single-cell analyses reveal heterogeneity of DNAM-1 receptor-ligand interactions that instructs intratumoral γδt-cell activity
10.1158/0008-5472.can-24-1509 · 2025 · External reference
Spatially resolved C1QC(+) macrophage-CD4(+) T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
10.1038/s41421-025-00811-2 · 2025 · External reference
Tumour vasculature at single-cell resolution
10.1038/s41586-024-07698-1 · 2024 · External reference
Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy
10.1007/s12032-023-02226-z · 2023 · External reference
Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment
10.1038/s41467-021-27599-5 · 2021 · External reference
CD8(+) T cell states in human cancer: insights from single-cell analysis
10.1038/s41568-019-0235-4 · 2020 · External reference
Single-nucleus RNA sequencing and spatial transcriptomics reveal an immunosuppressive tumor microenvironment related to metastatic dissemination during pancreatic cancer liver metastasis
10.7150/thno.108925 · 2025 · External reference
Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses
10.1016/j.cell.2017.04.014 · 2017 · External reference
Targeting tumor cell-to-macrophage communication by blocking vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis
10.7150/thno.94537 · 2024 · External reference
Molecular pathological classification of colorectal cancer-an update
10.1007/s00428-024-03746-3 · 2024 · External reference
The cancer-immunity cycle: indication, genotype, and immunotype
10.1016/j.immuni.2023.09.011 · 2023 · External reference
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop
10.1016/j.ccell.2022.11.002 · 2022 · External reference
Single-cell profiling of tumor-infiltrating TCF1/TCF7(+) T cells reveals a T lymphocyte subset associated with tertiary lymphoid structures/organs and a superior prognosis in oral cancer
10.1016/j.oraloncology.2021.105348 · 2021 · External reference
Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy
10.1016/j.ccell.2023.08.001 · 2023 · External reference
Pan-cancer mapping of single CD8(+) T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity
2024 · External reference
Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology
2025 · External reference
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
10.1016/j.ccell.2021.09.010 · 2021 · External reference
High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer
10.1038/s41588-025-02193-3 · 2025 · External reference
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma
10.1182/blood.2024024590 · 2024 · External reference
Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4(+) T cells in head and neck cancer
10.1038/s41467-025-59341-w · 2025 · External reference
Multimodal mapping of the tumor and peripheral blood immune landscape in Human pancreatic cancer
10.1038/s43018-020-00121-4 · 2020 · External reference
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
10.1038/s41591-021-01323-8 · 2021 · External reference
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
10.1016/j.cell.2025.03.018 · 2025 · External reference
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
10.1038/s41586-021-03651-8 · 2021 · External reference
Intestinal tissue-resident memory T cells: characteristics, spatial heterogeneity, age-related dynamics, and roles in disease regulation
10.1016/j.jare.2025.03.021 · 2026 · External reference
Immune microniches shape intestinal T(reg) function
10.1038/s41586-024-07251-0 · 2024 · External reference
Spatial organization of tissue-resident memory T cells
10.1016/j.immuni.2026.03.009 · 2026 · External reference
Innate immune cells in the tumor microenvironment
10.1016/j.ccell.2021.05.016 · 2021 · External reference
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth
10.1016/j.ccell.2025.12.021 · 2026 · External reference
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer
10.1038/s41467-024-49189-x · 2024 · External reference
Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer
10.1136/jitc-2024-011319 · 2025 · External reference
Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8(+) T cells
10.1136/jitc-2025-013027 · 2025 · External reference
CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer
10.1007/s00018-025-06056-2 · 2026 · External reference
USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells
10.1038/s41388-025-03425-w · 2025 · External reference
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
10.1126/science.adg1955 · 2024 · External reference
Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level
10.1158/2159-8290.cd-21-0316 · 2022 · External reference
Single-cell and spatial transcriptomics analysis of non-small cell lung cancer
10.1038/s41467-024-48700-8 · 2024 · External reference
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
10.1186/s13073-023-01164-9 · 2023 · External reference
SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts
10.1158/0008-5472.can-24-4916 · 2026 · External reference
ANGPTL2+cancer-associated fibroblasts and SPP1+macrophages are metastasis accelerators of colorectal cancer
2023 · External reference
Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 axis
10.1053/j.gastro.2021.08.023 · 2021 · External reference
You B: erα-dependent crosstalk between macrophages and cancer cells potentiates vasculogenic mimicry and M2 macrophage polarization in bladder cancer
10.1186/s12964-025-02297-7 · 2025 · External reference
Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis
10.1186/s13046-022-02499-8 · 2022 · External reference
The role of tumor-associated macrophages in the radioresistance of esophageal cancer cells via regulation of the VEGF-mediated angiogenic pathway
10.1007/s12026-024-09479-4 · 2024 · External reference
A blueprint for tumor-infiltrating B cells across human cancers
10.1126/science.adj4857 · 2024 · External reference
Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity
10.1038/s41590-025-02259-8 · 2025 · External reference
Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy
10.1002/ctm2.1346 · 2023 · External reference
Interferon regulatory factor 4 recruits immature B cells to signal tertiary lymphoid structure immaturity and progression of clear cell renal cell carcinoma
10.7150/ijbs.113737 · 2025 · External reference
CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo
10.1158/0008-5472.can-06-0889 · 2006 · External reference
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1
10.1182/blood-2008-05-157396 · 2008 · External reference
Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival
10.3389/fimmu.2021.778329 · 2021 · External reference
DA-DRD5 signaling reprograms B cells to promote CD8(+) T cell-mediated antitumor immunity
10.1016/j.celrep.2025.115364 · 2025 · External reference
Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody
10.1097/cji.0b013e3181ee6ba9 · 2010 · External reference
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer
10.1016/j.ccell.2023.12.012 · 2024 · External reference
Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+) tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy
10.1053/j.gastro.2023.10.022 · 2024 · External reference
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis
10.1016/j.ccell.2024.07.006 · 2024 · External reference
Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer
2025 · External reference
Cancer associated fibroblasts-derived lactate induces oxaliplatin treatment resistance by promoting cancer stemness via ANTXR1 lactylation in colorectal cancer
10.1016/j.canlet.2025.217917 · 2025 · External reference
CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma
10.1016/j.jhep.2024.09.044 · 2025 · External reference
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1
10.1186/s13046-023-02900-0 · 2023 · External reference
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
10.1038/s41422-020-0355-0 · 2020 · External reference
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer
10.1158/2159-8290.cd-19-1384 · 2020 · External reference
Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways
10.1016/j.lfs.2020.118389 · 2020 · External reference
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer
10.1371/journal.pone.0055146 · 2013 · External reference
Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape
10.1016/j.intimp.2024.112282 · 2024 · External reference
Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data
10.3389/fimmu.2022.1009789 · 2022 · External reference
Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity
10.1080/2162402x.2021.1950953 · 2021 · External reference
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
10.1073/pnas.1320318110 · 2013 · External reference
Cancer-associated fibroblasts-derived exosomal ZNF250 promotes the proliferation, migration, invasion, and immune escape of hepatocellular carcinoma cells by transcriptionally activating PD-L1
10.1002/jbt.23778 · 2024 · External reference
Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis
10.1016/j.isci.2024.109674 · 2024 · External reference
CD248 induces PD-L1 expression on cancer-associated fibroblasts to promote NSCLC immune escape
10.3389/fcell.2025.1635915 · 2025 · External reference
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma
10.1016/j.immuni.2024.04.006 · 2024 · External reference
CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κb/SDF-1α axis to enhance efficacy against pancreatic cancer
10.1016/j.ymthe.2023.09.010 · 2023 · External reference
NGR-modified cancer-associated fibroblast-derived exosomes deliver resveratrol to inhibit CXCR2/NF-κb signaling in myeloid-derived suppressor cells and reverse immune suppression in liver cancer
10.1016/j.intimp.2026.116326 · 2026 · External reference
VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients
10.1007/s00262-022-03156-x · 2022 · External reference
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function
10.1080/2162402x.2023.2300882 · 2024 · External reference
Lymphoma B cells remodel bone marrow stromal cells into extracellular matrix-producing cancer-associated fibroblasts
10.1182/bloodadvances.2024015616 · 2025 · External reference
Association of CCL21(+) CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma
10.1007/s00262-026-04348-5 · 2026 · External reference
Persistent spatial immune responses in glioblastoma following oncolytic virus therapy
10.1016/j.cytogfr.2026.02.003 · 2026 · External reference
Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma
10.1002/hem3.70145 · 2025 · External reference
Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer
10.1186/s12967-022-03510-8 · 2022 · External reference
Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics
2023 · External reference
LAMA4(+) CD90(+) eCAFs provide immunosuppressive microenvironment for liver cancer through induction of CD8(+) T cell senescence
10.1186/s12964-025-02162-7 · 2025 · External reference
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
10.1186/s13073-023-01218-y · 2023 · External reference
Extracellular matrix cancer-associated fibroblasts promote stromal fibrosis and immune exclusion in triple-negative breast cancer
10.1002/path.6395 · 2025 · External reference
Targeting LRRC15 in cancer-associated fibroblasts modifies the extracellular matrix and enhances tumor immune responses to suppress lung cancer progression
10.1158/0008-5472.can-25-2871 · 2026 · External reference
Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-tgfβ axis and immune suppression in aggressive thyroid cancer
10.1186/s12967-025-07307-3 · 2025 · External reference
Cancer-associated fibroblast-derived extracellular vesicles loaded with GLUT1 inhibitor synergize anti-PD-L1 to suppress tumor growth via degrading matrix stiffness and remodeling tumor microenvironment
10.1016/j.jconrel.2025.113998 · 2025 · External reference
Single-cell analysis reveals the COL11A1(+) fibroblasts are cancer-specific fibroblasts that promote tumor progression
2023 · External reference
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade
10.1038/s43018-022-00433-7 · 2022 · External reference
Intratumoral CXCL13(+) CD160(+) CD8(+) T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer
10.1136/jitc-2024-009603 · 2024 · External reference
Cancer-associated fibroblast spatial heterogeneity and EMILIN1 expression in the tumor microenvironment modulate TGF-β activity and CD8(+) T-cell infiltration in breast cancer
10.7150/thno.90627 · 2024 · External reference
CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor
10.1038/s41421-023-00529-z · 2023 · External reference
Fibroblast Activation protein (FAP)(+) cancer-associated fibroblasts induce macrophage M2-like polarization via the fibronectin 1-integrin α5β1 axis in breast cancer
10.1038/s41388-025-03359-3 · 2025 · External reference
COL10A1(+) fibroblasts promote colorectal cancer metastasis and M2 macrophage polarization with pan-cancer relevance
10.1186/s13046-025-03510-8 · 2025 · External reference
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases
10.1136/gutjnl-2024-333617 · 2025 · External reference
Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts
10.1158/1078-0432.ccr-22-2041 · 2023 · External reference
TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1(+) macrophages
10.1038/s41588-025-02380-2 · 2025 · External reference
CAF-secreted LOX promotes PD-L1 expression via histone lactylation and regulates tumor EMT through tgfβ/IGF1 signaling in gastric cancer
10.1016/j.cellsig.2024.111462 · 2024 · External reference
Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κb and TGF-β2 signaling
10.1186/s12929-022-00888-x · 2022 · External reference
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy
10.1080/2162402x.2022.2144669 · 2022 · External reference
Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer
10.1016/j.celrep.2022.111929 · 2023 · External reference
SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer
10.1038/s41598-024-76298-w · 2024 · External reference
A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer
10.1158/2159-8290.cd-25-1774 · 2026 · External reference
STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma
10.1016/j.devcel.2025.01.014 · 2025 · External reference
Metabolism archetype cancer cells induce protumor TREM2(+) macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma
10.1038/s41467-025-62132-y · 2025 · External reference
Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling
10.1186/s12906-025-05020-8 · 2025 · External reference
HMGB1/TREM2 positive feedback loop drives the development of radioresistance and immune escape of glioblastoma by regulating TLR4/Akt signaling
10.1186/s12967-024-05489-w · 2024 · External reference
Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer
10.1186/s13046-024-03124-6 · 2024 · External reference
Targeted reprogramming of TREM2-positive macrophages and MRI-guided immune monitoring in colorectal cancer using CSF1R@Mn@MPDA-Antitrem2 nanoplatform
10.1002/adhm.202501027 · 2025 · External reference
Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer
10.1186/s12943-023-01830-x · 2023 · External reference
TREM2 Depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1β(+) macrophages
10.1053/j.gastro.2025.01.244 · 2025 · External reference
Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma
10.3389/fimmu.2024.1502936 · 2024 · External reference
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
10.1136/jitc-2023-006896 · 2023 · External reference
Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+)trm cell response to PD-1 blockade in gastric cancer
2023 · External reference
CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation
10.1111/cas.16371 · 2025 · External reference
CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer
10.1172/jci.insight.157215 · 2022 · External reference
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/jak/Stat3 in PD-L1-high lung cancer
10.1136/jitc-2024-010612 · 2025 · External reference
PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway
10.1038/s41392-023-01337-3 · 2023 · External reference
Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer
10.1038/s41416-024-02917-y · 2025 · External reference
Spatial dynamics of CD39(+)CD8(+) exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
10.1038/s41467-024-53262-w · 2024 · External reference
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction
10.1136/jitc-2024-009140 · 2025 · External reference
Association of baseline tumor-specific neoantigens and CD8(+) T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors
2024 · External reference
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
10.1136/jitc-2023-008056 · 2024 · External reference
Predictive value of baseline FDG-PET/CT for the durable response to immune checkpoint inhibition in NSCLC patients using the morphological and metabolic features of primary tumors
10.3390/cancers14246095 · 2022 · External reference
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
10.1016/j.ejca.2021.01.036 · 2021 · External reference
Revisiting the CXCL13/CXCR5 axis in the tumor microenvironment in the era of single-cell omics: implications for immunotherapy
10.1016/j.canlet.2024.217278 · 2024 · External reference
Beyond T cell toxicity - intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: a two-case series and literature review
10.1111/ene.16279 · 2024 · External reference
High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer
2025 · External reference
SRSF3 Promotes angiogenesis in colorectal cancer by splicing SRF
2022 · External reference
Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR
10.1007/s00432-022-04300-x · 2023 · External reference
Early changes in lymphocyte/monocyte ratio on treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with Immune checkpoint inhibitors
10.1080/07357907.2025.2557004 · 2025 · External reference
Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer
10.1016/j.euo.2023.08.009 · 2024 · External reference
Therapy-induced evolution of Human lung cancer revealed by single-cell RNA sequencing
10.1016/j.cell.2020.07.017 · 2020 · External reference
The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients
10.1080/2162402x.2019.1652538 · 2019 · External reference
Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer
10.1136/jitc-2023-008386 · 2024 · External reference
Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy
10.1016/j.drup.2025.101292 · 2025 · External reference
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector treg cells for homologous-recombination-deficient tumors
10.1016/j.cell.2024.06.013 · 2024 · External reference
CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity
10.1016/j.immuni.2023.06.003 · 2023 · External reference
CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk
10.1186/s12929-025-01192-0 · 2025 · External reference
ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance
10.1016/j.cellsig.2026.112398 · 2026 · External reference
Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance
10.1080/2162402x.2024.2330194 · 2024 · External reference
Antigen-presenting CAFs orchestrate immunosuppressive niches via CXCL13-mediated immune cell infiltration dysregulation and prognostic stratification in triple-negative breast cancer
10.1016/j.intimp.2025.115193 · 2025 · External reference
CXCL13 expression promotes CAR T cell antitumor activity and potentiates response to PD-1 blockade
10.1002/advs.202508095 · 2025 · External reference
Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs
10.1038/s41598-023-29450-x · 2023 · External reference
Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1(+) cDC1 infiltration and activates anti-tumor immunity
10.1038/s41467-025-68018-3 · 2025 · External reference
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
10.1136/jitc-2022-004561 · 2022 · External reference
Nanoparticle-mediated CXCL12-CXCR4 inhibition reprograms macrophages and suppresses gastric carcinoma
10.1002/advs.202500225 · 2025 · External reference
TGF-β1-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12
10.1053/j.gastro.2024.02.025 · 2024 · External reference
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in pancreatic cancer: CXCL12 predicts survival of radically resected patients
10.3390/cells11213340 · 2022 · External reference
Pillarisetty VG: the CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
10.1016/j.semcancer.2019.12.007 · 2020 · External reference
CXCR4(+) mammary gland macrophageal niche promotes tumor initiating cell activity and immune suppression during tumorigenesis
10.1038/s41467-025-59972-z · 2025 · External reference
CXCL12/CXCR4 axis governs treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer
2025 · External reference
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis
2025 · External reference
Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer
10.1016/j.ejps.2020.105606 · 2021 · External reference
USP15 Facilitates colorectal cancer immune evasion through SMYD3/CCL2-dependent myeloid-derived suppressor cell recruitment
10.1158/2326-6066.cir-24-1194 · 2025 · External reference
SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1
10.7150/thno.101575 · 2024 · External reference
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion
10.1186/s12931-025-03263-0 · 2025 · External reference
Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways
10.1186/s13058-023-01684-7 · 2023 · External reference
Oncolytic virus-induced IL-1β(+) monocyte-IL-6(+) CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
10.1136/jitc-2025-013175 · 2025 · External reference
Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma
10.1080/2162402x.2022.2146860 · 2022 · External reference
Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC
10.1186/s12967-024-06018-5 · 2024 · External reference
Tetrahydrocurcumin alleviates colorectal tumorigenesis by modulating the SPP1/CD44 axis and preventing M2 tumor-associated macrophage polarization
10.1016/j.phymed.2025.156674 · 2025 · External reference
YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-tgfβ signaling to facilitate PD-L1 expression in M2-like TAMs
10.1016/j.yexcr.2021.112655 · 2021 · External reference
scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer
10.1186/s12967-025-06485-4 · 2025 · External reference
Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer
10.1007/s00262-020-02676-8 · 2021 · External reference
ID1 expressing macrophages support cancer cell stemness and limit CD8(+) T cell infiltration in colorectal cancer
10.1038/s41467-023-43548-w · 2023 · External reference
SLC2A1(+) tumour-associated macrophages spatially control CD8(+) T cell function and drive resistance to immunotherapy in non-small-cell lung cancer
10.1038/s41556-025-01840-5 · 2026 · External reference
FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity
10.1016/j.jhep.2024.09.029 · 2025 · External reference
VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk
10.7150/ijbs.86085 · 2024 · External reference
Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer
10.1126/sciimmunol.adp3978 · 2025 · External reference
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
10.1016/j.ccell.2025.07.013 · 2025 · External reference
ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis
10.1136/jitc-2025-011564 · 2025 · External reference
Tumor-infiltrating mast cells stimulate ICOS(+) regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression
10.1016/j.jare.2023.04.013 · 2024 · External reference
Positioning and reversible suppression of CCR7(+) dendritic cells in perivascular tumor niches shape cancer immunity
10.1016/j.immuni.2025.11.020 · 2026 · External reference
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader and antagonist, for the treatment of advanced prostate cancer
10.1158/1078-0432.ccr-25-0471 · 2026 · External reference
Cancer-associated VEGFR2(R1032Q) sustains receptor activation also by promoting ligand-independent hetero-dimerization with co-expressed wild-type VEGFR2 and translocation into lipid rafts
10.1016/j.neo.2025.101195 · 2025 · External reference
IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
10.1016/j.ccell.2022.11.014 · 2023 · External reference
TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer
10.1016/j.canlet.2023.216510 · 2024 · External reference
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion
10.1016/j.cell.2024.01.008 · 2024 · External reference
Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer
10.1016/j.radonc.2019.11.003 · 2020 · External reference
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy
10.3389/fimmu.2025.1557461 · 2025 · External reference
Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer
10.1016/j.ejca.2025.115320 · 2025 · External reference
Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer
10.1158/1078-0432.ccr-25-2566 · 2026 · External reference
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
10.1016/j.ccell.2023.09.006 · 2023 · External reference
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
10.1158/2159-8290.cd-24-0991 · 2025 · External reference
ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer
10.1172/jci181517 · 2025 · External reference
Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma
2025 · External reference
Berberine derivative B68 promotes tumor immune clearance by dual-targeting BMI1 for senescence induction and CSN5 for PD-L1 degradation
2025 · External reference
PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κb pathway and PD-L1 expression
10.1136/jitc-2023-007627 · 2023 · External reference
Cancer-associated-fibroblast-mediated paracrine and autocrine SDF-1/CXCR4 signaling promotes stemness and aggressiveness of colorectal cancers
10.3390/cells13161334 · 2024 · External reference
Targeting the CXCR4/CXCL12 axis to overcome drug resistance in triple-negative breast cancer
10.3390/cells14181482 · 2025 · External reference
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine sirpγ-derived CD47 blocker
10.1038/s41467-024-54129-w · 2024 · External reference
Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
2024 · External reference
Lypd6b depletion promotes CD8(+) T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer
10.1038/s41467-025-67344-w · 2025 · External reference
FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma
10.1158/0008-5472.can-23-0966 · 2024 · External reference
An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer
10.1016/j.ccell.2019.08.008 · 2019 · External reference
Increases in 4-acetaminobutyric acid generated by phosphomevalonate kinase suppress CD8(+) T cell activation and allow tumor immune escape
10.1002/advs.202403629 · 2024 · External reference
Emerging biomarkers in melanoma: bridging molecular discovery and precision oncology
10.1016/j.canlet.2026.218359 · 2026 · External reference
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer
10.1016/j.immuni.2023.11.002 · 2023 · External reference
QSOX1 facilitates dormant esophageal cancer stem cells to evade immune elimination via PD-L1 upregulation and CD8 T cell exclusion
10.1073/pnas.2407506121 · 2024 · External reference
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
10.1136/gutjnl-2022-327909 · 2023 · External reference
Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy
10.1126/scitranslmed.abq3558 · 2023 · External reference
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
10.7150/thno.52435 · 2021 · External reference
PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy
10.1002/hem3.142 · 2024 · External reference
Tumor-associated NK cells regulate distinct CD8+ T-cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers
10.1158/2159-8290.cd-24-1232 · 2025 · External reference
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
10.1080/2162402x.2022.2034257 · 2022 · External reference
A CD4+ T lymphocyte-specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity
10.1172/jci191119 · 2025 · External reference
Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell
10.1080/19490976.2023.2249143 · 2023 · External reference
PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer
10.1186/s13046-024-03080-1 · 2024 · External reference
PI3Kγ inhibition drives M1 macrophage differentiation and synergizes with PD-L1 blockade to improve survival in poorly immunogenic head and neck squamous cell carcinoma
10.1080/15384047.2025.2600701 · 2026 · External reference
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
10.1136/gutjnl-2024-333492 · 2025 · External reference
Modified Jian-pi-yang-zheng decoction inhibits gastric cancer progression via the macrophage immune checkpoint PI3Kγ
10.1016/j.biopha.2020.110440 · 2020 · External reference
Chemotherapy boosts anti-angiogenic and anti-PD-1 combination therapy through activation of cCAS-STING pathway in colon cancer
10.1016/j.intimp.2025.114212 · 2025 · External reference
Self-assembled acid-responsive nanosystem for synergistic anti-angiogenic/photothermal/ferroptosis therapy against esophageal cancer
10.1002/adhm.202302787 · 2024 · External reference
Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer
10.1158/2159-8290.cd-21-1248 · 2022 · External reference
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
10.1038/s41467-025-58289-1 · 2025 · External reference
Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer
2024 · External reference
Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer
10.1016/j.phrs.2024.107314 · 2024 · External reference
Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer
10.1126/scitranslmed.adj9366 · 2024 · External reference
A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy
10.7150/thno.101001 · 2025 · External reference
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
10.1016/j.cell.2024.04.025 · 2024 · External reference
Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy
10.1016/j.ccell.2025.02.014 · 2025 · External reference
NAT10/ac4C/FOXP1 Promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer
10.1002/advs.202302705 · 2023 · External reference
IL1R1(+) cancer-associated fibroblasts drive tumor development and immunosuppression in colorectal cancer
10.1038/s41467-023-39953-w · 2023 · External reference
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
10.1186/s13058-025-02020-x · 2025 · External reference
Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity
10.1080/15548627.2024.2439657 · 2025 · External reference
CAA-derived IL-6 promoted the PD-L1 expression of breast cancer via STAT3/miR-497a-5p signaling
10.1007/s00432-025-06324-5 · 2025 · External reference
CXCL5 impedes CD8(+) T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis
10.1186/s13046-024-03122-8 · 2024 · External reference
XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells
10.1158/1078-0432.ccr-24-2449 · 2025 · External reference
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
10.1136/jitc-2022-005627 · 2023 · External reference
